Skip to content

Study on the Clinical Efficacy and Mechanism of Sansegao in the Treatment of Osteoporotic Vertebral Fractures after Percutaneous Vertebroplasty

Study on the Clinical Efficacy and Mechanism of Tricolor Ointment in the Treatment of Osteoporotic Vertebral Fractures after Percutaneous Vertebroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001184
Enrollment
Unknown
Registered
2026-05-07
Start date
2025-04-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Treatment group:sansegao: change once every 2 days, 1 sheet each time, apply externally, continue for 4 weeks
Calcitriol Capsules: Take once daily, 1 capsule each time, orally after dinner, for 4 weeks.
Control group:Calcitriol Capsules: Take once daily, 1 capsule each time, orally after dinner, for 4 weeks.

Sponsors

Spine Surgery Department,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Women aged >55 and 60 and <80. 2. Meet the diagnostic criteria for osteoporotic fractures and undergo PVP surgery; 3. Patients who meet the diagnostic criteria of traditional Chinese medicine syndromes; 4. Patients who agree to participate in the treatment and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Secondary osteoporosis caused by other diseases or medications includes endocrine diseases (such as hyperparathyroidism, diabetes, etc.), multiple myeloma, long-term use of glucocorticoids, metastatic bone tumors, thoracolumbar tuberculosis, and bone abnormalities; 2. Pain-causing diseases such as lumbar disc herniation, degenerative spondylosis, lumbar spinal stenosis, spondylolisthesis, and ankylosing spondylitis; with motor, sensory impairments, and abnormalities in urination and defecation; 3. Patients with mental illness, senile dementia, severe neurosis, etc., who cannot evaluate treatment efficacy, provide accurate information about their condition, or cooperate; 4. Individuals allergic to the ingredients of tricolor plaster; patients who have participated in other clinical trials in the past 3 months; 5. Those with multi-organ failure including heart, lung, and kidney dysfunction; 6. Patients with incomplete clinical data, who refuse follow-up, or whose contact information is missing; 7. Individuals unable to care for themselves, requiring medical care, having unstable gait, or prone to falls.

Design outcomes

Primary

MeasureTime frame
visual analogue scale, VAS;

Secondary

MeasureTime frame
bone mineral density,BMD;Oswestry Disability Index;Basic activities of daily living (BADL);

Countries

China

Contacts

Public ContactZhang Dong

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

zhangdong_ehbh@126.com18801792029

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026